- Total Sales Increase 13.6% (11% at Constant Currency)
- 14.3% Increase in EPS (excluding unusual charges from 2003)
- Arthroscopy sales increase 20.6% to $50.3 million -
UTICA, N.Y., April 22 /PRNewswire-FirstCall/ -- CONMED Corporation
(Nasdaq: CNMD) announced today its financial results for the first quarter
ended March 31, 2004.
Sales increased 13.6% in the first quarter of 2004 to $134.0 million
($131.0 million at constant exchange rates) compared to $118.0 million in the
first quarter of 2003. GAAP net income for the first quarter grew to $12.0
million, or $0.40 per diluted share, on a 3% increase in diluted shares
outstanding, compared to $6.7 million, or $0.23 per diluted share, in last
year's first quarter. Excluding acquisition and financing charges and a gain
on a settlement of a legal dispute (please see attached reconciliation for
full explanation), non-GAAP net income for the first quarter of 2003 was $10.0
million, or $0.35 per diluted share.
Key highlights for the first quarter included:
- Linvatec, CONMED's sports medicine technology subsidiary, unveiled
fourteen new products at the American Academy of Orthopedic Surgeons
Annual Meeting;
- CONMED announced a strategic partnership with eTrauma; and
- CONMED teamed up with Dolphin, a subsidiary of OSI Systems
(Nasdaq: OSIS) to become its exclusive North American distributor for a
full line of pulse oximetry products manufactured by Dolphin.
Sales of the Company's orthopedic products grew 15.3% to $83.8 million
from $72.7 million in last year's first quarter. Arthroscopy sales increased
20.6% to $50.3 million (9.0% internal growth, 3.7% foreign currency, and 7.9%
from the Bionx acquisition) compared to $41.7 million in the same period a
year ago. Powered instrument sales grew 8.1% to $33.5 million (3.3% internal
growth and 4.8% from foreign currency) compared to $31.0 million in the first
quarter of 2003 on the continued strength of the PowerProb line of products.
Electrosurgery revenues were $20.2 million, an increase of 20.2%, compared
to sales of $16.8 million in the 2003 first quarter. Sales of Patient Care
Products increased 4.0% to $18.0 million compared to $17.3 million. Endoscopy
revenues grew 2.8% to $11.0 million compared to first quarter 2003 sales of
$10.7 million. The Integrated Systems product line had sales of $1.0 million
in the first quarter of 2004 compared to $0.5 million in the comparable period
of 2003.
Mr. Joseph J. Corasanti, President and Chief Operating Officer, said,
"CONMED's sales growth in the first quarter of 2004 is a repeat of the robust
performance we experienced in the fourth quarter of 2003. More than ever we
believe that our dynamic strategy of adding depth to our product lines through
organic development and acquisitions of companies like Bionx Implants and CORE
Dynamics helped CONMED reach record sales levels. We are very pleased to see
domestic Arthroscopy sales increase 7.5% organically, excluding the effects of
the Bionix acquisition. Our growth was also aided by the additions of new
complementary and supplementary products to an excellent sales force that
continues to grow in size. We believe this strategy will result in sales
growth levels consistent with or better than market growth rates."
"We also made significant progress in improving our balance sheet during
the first quarter. Our strong cash flow enabled us to pay down $23 million in
debt during the quarter, and we continued to make progress in managing our
working capital by again reducing the days outstanding in inventory."
The Company's diluted earnings per share for the 2004 first quarter, was
consistent with previously provided guidance of $0.39 to $0.43. Diluted
earnings per share would have been even stronger absent two matters that
occurred during the quarter. First, the Company incurred foreign currency
transaction losses on certain balance sheet items due to the strengthening of
the U.S. dollar during March 2004. Second, while the Company's gross margin
was within the historical range, it was somewhat lower than had been
anticipated as the mix of products sold favored lower margin products.
Mr. Corasanti concluded, "We remain confident that we are on the right
track with our growth strategy as evidenced by our better than expected top-
line growth for the quarter and our strong cash flow. The investments we have
made in sales, marketing and research are beginning to bear fruit.
Consequently, we reaffirm our forecast for 2004 diluted earnings per share
estimate of approximately $1.70 to $1.74. As for the upcoming second quarter,
our experience tells us that the Company's second quarter sales are typically
slightly lower than those for the first quarter, as hospitals tend to use
their newly authorized annual capital budgets to a greater extent in the first
quarter. Consequently, for the three months ended June 30, 2004, we expect to
generate sales of approximately $127 million to $131 million and diluted
earnings per share in the range of $0.38 to $0.42.
CONMED Profile
CONMED is a medical technology company specializing in instruments,
implants, and video equipment for arthroscopic sports medicine, and powered
surgical instruments, such as drills and saws, for orthopedic, ENT, neuro-
surgery, and other surgical specialties. The Company is also a leading
developer, manufacturer and supplier of RF electrosurgery systems used
routinely to cut and cauterize tissue in nearly all types of surgical
procedures worldwide, endoscopy products such as trocars, clip appliers,
scissors, and surgical staplers. The Company offers integrated operating room
design and intensive care unit service managers. The Company also
manufactures and sells a full line of ECG electrodes for heart monitoring and
other patient care products. Headquartered in Utica, New York, the Company's
2,600 employees distribute its products worldwide from eleven manufacturing
locations.
Forward Looking Information
This press release contains forward-looking statements based on certain
assumptions and contingencies that involve risks and uncertainties. The
forward-looking statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995 and relate to the
Company's performance on a going-forward basis. The forward-looking
statements in this press release involve risks and uncertainties which could
cause actual results, performance or trends, including the above mentioned
anticipated revenues and earnings, to differ materially from those expressed
in the forward-looking statements herein or in previous disclosures. The
Company believes that all forward-looking statements made by it have a
reasonable basis, but there can be no assurance that management's
expectations, beliefs or projections as expressed in the forward-looking
statements will actually occur or prove to be correct. In addition to general
industry and economic conditions, factors that could cause actual results to
differ materially from those discussed in the forward-looking statements in
this press release include, but are not limited to: (i) the failure of any one
or more of the assumptions stated above, to prove to be correct; (ii) the
risks relating to forward-looking statements discussed in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2003; (iii)
cyclical purchasing patterns from customers, end-users and dealers; (iv)
timely release of new products, and acceptance of such new products by the
market; (v) the introduction of new products by competitors and other
competitive responses; (vi) the possibility that any new acquisition or other
transaction may require the Company to reconsider its financial assumptions
and goals/targets; and/or (vii) the Company's ability to devise and execute
strategies to respond to market conditions.
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended March 31, 2003 and 2004
(In thousands except per share amounts)
(unaudited)
2003 2004
Net sales $118,034 $133,964
Cost of sales 55,966 63,605
Cost of sales, nonrecurring - Note A 412 -
Gross profit 61,656 70,359
Selling and administrative expense 37,145 43,793
Research and development expense 3,703 4,739
Write-off of purchased in-process research
and development assets - Note B 7,900 -
Other expense (income), net - Note C (7,658) -
41,090 48,532
Income from operations 20,566 21,827
Loss on early extinguishment of debt 166 -
Interest expense 5,538 3,306
Income before income taxes 14,862 18,521
Provision for income taxes 8,194 6,482
Net income $6,668 $12,039
Per share data:
Net income
Basic $.23 $.41
Diluted .23 .40
Weighted average common shares
Basic 28,876 29,303
Diluted 29,037 29,992
Note A - Included in cost of sales in the three months ended March 31,
2003 are approximately $.4 million in acquisition-related costs.
Note B - In the three months ended March 31, 2003, we wrote off $7.9
million of purchased in-process research and development assets in
connection with the Bionx acquisition. No benefit for income taxes was
recorded on the write-off as these costs are not deductible for income
tax purposes.
Note C - Included in other expense (income) in the three months ended
March 31, 2003 are a $9.0 million gain on the settlement of a contractual
dispute and $1.3 million in acquisition-related costs.
CONMED CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
ASSETS
(unaudited)
December 31, March 31,
2003 2004
Current assets:
Cash and cash equivalents $5,986 $9,467
Accounts receivable, net 60,449 61,884
Inventories 120,945 115,214
Deferred income taxes 10,188 10,084
Other current assets 3,538 3,424
Total current assets 201,106 200,073
Property, plant and equipment, net. 97,383 96,302
Goodwill and other assets, net 506,569 504,257
Total assets $805,058 $800,632
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $4,143 $3,906
Other current liabilities 50,712 44,829
Total current liabilities 54,855 48,735
Long-term debt 260,448 237,507
Other long-term liabilities 56,265 60,375
Total liabilities 371,568 346,617
Shareholders' equity:
Capital accounts 236,948 245,520
Retained earnings 194,473 206,512
Accumulated other comprehensive income 2,069 1,983
Total equity 433,490 454,015
Total liabilities and shareholders' equity $805,058 $800,632
OTHER FINANCIAL INFORMATION
(unaudited, in thousands)
Three months ended
March 31,
2003 2004
Depreciation $2,374 $2,645
Amortization 2,946 3,934
Capital expenditures 1,710 1,620
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO NET INCOME
BEFORE NONRECURRING ITEMS
Three Months Ended March 31, 2003 and 2004
(In thousands except per share amounts)
(unaudited)
2003 2004
Reported net income $6,668 $ 12,039
Acquisition-related costs included in cost of sales 412 -
Write-off of purchased in-process research
and development assets 7,900 -
Gain on settlement of a contractual dispute,
net of legal costs (9,000) -
Other acquisition related costs 1,342 -
Total other expense (income), net (7,658) -
Loss on early extinguishment of debt 166 -
Nonrecurring income before income taxes 820 -
Provision for income taxes on nonrecurring income 2,549 -
Net income before nonrecurring items. $10,037 $ 12,039
Per share data:
Reported net income
Basic $0.23 $0.41
Diluted 0.23 0.40
Net income before nonrecurring items
Basic $0.35 $0.41
Diluted 0.35 0.40
Management has provided the above reconciliation of net income before
nonrecurring items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance.
SOURCE CONMED Corporation
 back to top
Related links:
http://www.conmed.com
Company News On-Call:
http://www.prnewswire.com/comp/201850.html
CONTACT:
Robert Shallish, Chief Financial Officer of
CONMED Corporation, +1-315-624-3206; or Investors, Lanie Marcus,
or Media, Julie Huang, both of Financial Dynamics,
+1-212-850-5600, for CONMED Corporation
|
